Last reviewed · How we verify
PCV15
At a glance
| Generic name | PCV15 |
|---|---|
| Also known as | VAXNEUVANCE, VAXNEUVANCE™, VAXNEUVANCE™;, PPS23, PCV15 and PPS23 |
| Sponsor | Pfizer |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) (PHASE3)
- Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7) (PHASE3)
- MISP 60528 Pneumococcal Vaccination
- A Study to Learn About How a New Pneumococcal Vaccine Works in Infants (PHASE2)
- Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15 (PHASE4)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6) (PHASE3)
- Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age (PHASE1)
- Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PCV15 CI brief — competitive landscape report
- PCV15 updates RSS · CI watch RSS
- Pfizer portfolio CI